Antibiotic potentiator OTX001

By potentiating existing antibiotics we can potentially offer clinicians many more treatment options when treating resistant infections.

This has the potential to be a “first in class” drug. At the used concentration our drug is not active by itself limiting resistance development.

  • Antimicrobial compounds
  • Alternative antimicrobials
  • Infection prevention
  • Antimicrobial stewardship
  • Microbial diagnostics
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Viruses
  • Fungi
  • Yeasts
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Development
  • Validation
  • Research
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • License
  • Co-develop
  • Outsource
  • Joint Venture
  • Sell

Funding organisation:

    Infectious disease area:

      Geographic origin:

        Venture Capital consortium and/or major pharmaceutical company

        Omnicin Therapeutics, is an early stage pharmaceutical company, developing potentiators for existing antibiotics.


        What is going on with AMR?
        Stay tuned with remarkable global AMR news and developments!